Atrial Flutter Clinical Trial
Official title:
Atrial Flutter Ablation in a Real World Population: A Multicenter Italian Registry (The LEONARDO Study)
The "LEONARDO" study is a non-randomized, multicenter, prospective study in which consecutive patients indicated for Atrial Flutter isthmus-dependent (AFL) ablation will be enrolled. Patients can be treated with any market released catheter for ablation. The decision to perform the ablation of AFL will be made based on clinical evaluation of the investigators according to their clinical practice. The study does not require specific surgical techniques. Patient time commitment for the study is approximately 12 months.The study has been designed to describe the italian clinical practice in relation to the approach of AFL ablation. In particular, the investigators will describe the methods for the validation of ablation success, the techniques adopted, and the patient management approaches in the participating centers.
Catheter ablation of Atrial Flutter has become an accepted alternative to pharmacologic therapy.The current guidelines recommend the catheter ablation at the first episode of AFL (Class IIa) or in any case of recurrent episodes of AFL (Class I). Recent studies have already demonstrated a high degree of procedural efficacy (higher than 90%). However, there are still two main areas of investigation. First, what is the best method to obtain an effective lesion. Second, what is the most reliable method to validate the procedure success.The present study is aimed at investigating these aspects in the current Italian clinical practice. ;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Terminated |
NCT02317029 -
Comparison of Oxygen Interventions and Defibrillator Efficiency
|
N/A | |
Recruiting |
NCT01563848 -
Cryoablation in Patients With Atrial Flutter
|
Phase 2 | |
Completed |
NCT01229254 -
Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter
|
Phase 2 | |
Completed |
NCT02065388 -
Pharmacogenetic Dosing of Warfarin
|
Phase 3 | |
Completed |
NCT00839657 -
Clarification of Optimal Anticoagulation Through Genetics
|
Phase 3 | |
Completed |
NCT00232232 -
Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia
|
Phase 4 | |
Completed |
NCT04884100 -
enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening
|
N/A | |
Completed |
NCT05468281 -
RAFF5 Proposal: Improve the Quality and Safety of Patients Seen in the Emergency Department for Acute Atrial Fibrillation and Flutter
|
||
Completed |
NCT03627143 -
Decreasing Hospital Admissions From the ED for AAFF
|
N/A | |
Completed |
NCT02917538 -
A Randomized Trial of Contact Force in Atrial Flutter Ablation
|
N/A | |
Enrolling by invitation |
NCT05903313 -
A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
|
||
Recruiting |
NCT05755074 -
Ablation of Typical Right Atrial Flutter
|
N/A | |
Recruiting |
NCT05883631 -
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
|
N/A | |
Recruiting |
NCT03272620 -
Atrial Fibrillation at the Viennese University Emergency Department
|
N/A | |
Completed |
NCT02810938 -
MIFI Flutter Registry - Ablation of Atrial Flutter With IntellaTip Sensor Technology
|
||
Completed |
NCT01914497 -
Dipole Density Mapping of Typical Atrial Flutter
|
N/A | |
Completed |
NCT02268799 -
High Sensitivity Troponin T Levels Following DC Cardioversion for Atrial Fibrillation / Atrial Flutter
|
N/A | |
Active, not recruiting |
NCT01976507 -
Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
|
Phase 4 | |
Completed |
NCT00232310 -
Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr
|
Phase 2 |